Nabriva Therapeutics Reports 2017 Financial Results and Recent Corporate Highlights

– Positive topline results from pivotal LEAP 1 trial announced in September 2017 , with read-out from second Phase 3 trial, LEAP 2, expected in the spring of 2018 – – $86.9 million cash and investments as of December 31, 2017 – DUBLIN, Ireland , March 16, 2018 (GLOBE NEWSWIRE) — Nabriva

READ FULL TEXT

Leave a Reply

Your email address will not be published.